Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · HERON THERAPEUTICS, INC. /DE/ (HRTX)

Heron Therapeutics Q2 revenue $37.7M, up 1.3%; withdraws 2026 guidance

Negative Impact 4 of 5 guidance Written later

Heron Therapeutics reported second-quarter 2026 net revenue of $37.7 million, up 1.3% from a year earlier, while its net loss widened to $5.5 million from $2.4 million. The company withdrew its full-year 2026 net product sales and Adjusted EBITDA guidance after a June 2026 court decision on CINVANTI patents made the timing of potential generic entry hard to forecast, and it said it is considering strategic alternatives with no timetable set.

Key points

  • Q2 2026 net revenue was $37.7 million, up 1.3% from $37.2 million in Q2 2025; CINVANTI revenue fell 9.7% to $21.8 million.
  • Q2 2026 net loss was $5.5 million, or $0.03 per share, compared with a net loss of $2.4 million, or $0.02 per share, a year earlier.
  • Full-year 2026 guidance was withdrawn, citing the June 2026 U.S. District Court for the District of Delaware decision on CINVANTI patents.
  • Cash, cash equivalents and short-term investments totaled $42.7 million at June 30, 2026; the Hercules Capital credit facility was amended with a $13.5 million principal reduction at execution.

The filing

CompanyHERON THERAPEUTICS, INC. /DE/ (HRTX)
Form8-K, current report
Filed with the SECAug 10, 2026, 8:00 AM ET
Accession number0001193125-26-341300

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.